- Safety study is part of the development of Estelle®, Mithra’s combined oral contraceptive candidate
- Aim of the study is to analyze a broad range of safety parameters for Estelle®, including hemostatic, endocrine and metabolic markers
Liège, Belgium, 21 June 2017 – Mithra (Euronext Brussels: MITRA), a company specialized in Women’s Health, announces that it has completed recruitment into a safety study to evaluate the effect of Estelle® on endocrine function (thyroid, adrenal), metabolic control (lipid and carbohydrate metabolism) as well as on a broad panel of hemostasic markers. Estelle® is Mithra’s combined oral contraceptive (COC) candidate, composed of 15 mg Estetrol (E4) and 3 mg drospirenone (DRSP). Estelle® is currently being tested in two Phase III trials in Europe/Russia and in the US/Canada, the results of which are expected in Q3 2018 and Q1 2019, respectively.